Skip to main content

Helixgate

Skip to main content

Helixgate

Uncategorized

Immune Evasion Uncovered by Virome-Wide Ubiquitin Ligase Discovery

Published

on

In a new study published in Science titled, “Virome-wide ubiquitin ligase discovery reveals diverse mechanisms of immune evasion,” researchers from Harvard Medical School (HMS) have uncovered how viruses hijack cells’ garbage-disposal systems to evade immune attack. 

The study applies ORFeome, a tool that broadens the scale by which researchers study viral proteins. The advance proposes to speed basic discoveries in virology, inform the development of new vaccines and treatments to protect against emerging pathogens. 

“This library reveals how viruses manipulate human cells on a scale that simply wasn’t possible before,” said Stephen Elledge, PhD, professor of genetics and medicine at Harvard Medical School and senior author of the study. “We believe it changes virology from studying one virus at a time to discovering the common strategies and surprising innovations that viruses have evolved, providing a powerful new foundation for understanding emerging viral threats.” 

ORFeome and other ORF libraries are named after open reading frames, DNA sequences that encode proteins. Previous viral ORF libraries from other groups focused on individual viruses or virus families that contained 100 or 200 sequences each. The new ORFeome contains about 13,000 physical DNA sequences, or constructs, that code for about 9,000 proteins from 513 different viruses, including Andes hantavirus, Ebola virus, and Zika virus. 

“Most viruses have never been studied in detail, yet evolution has already performed countless experiments for us. This library gives us a way to read the results of those experiments across the viral world,” said Elledge, who is also a Howard Hughes Medical Institute (HHMI) Investigator. 

The team attached a genetic barcode to each ORF, allowing researchers to conduct studies of all 13,000 ORFs at once. 

“We can insert the sequences into a population of cells, ask questions like which ones cause the cells to grow better or less, and then identify those by their barcodes when the experiment is finished,” said Colin O’Leary, PhD, HMS research fellow and co-author on the study. “It hasn’t been possible before to do genetic screens like this with viral proteins.” 

The team will make the ORFeome freely available for the research community. Elledge and colleagues implemented a flexible design to enable application to other model systems and experiments. 

The team conducted genetic screens in three cell types, searching for viral proteins that affect cell proliferation, stop cells from presenting antigens to trigger the immune system to attack, or block the effects of interferon. Results uncovered more than 700 viral proteins that contribute to at least one of those actions. 

The study opens opportunities to design drugs that hinder viral activity while sparing normal function. 

The post Immune Evasion Uncovered by Virome-Wide Ubiquitin Ligase Discovery appeared first on GEN – Genetic Engineering and Biotechnology News.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

New webinar: Tackling drug discovery challenges in cancer research

Published

on

Cancer cells

Hosted by Drug Discovery World and supported by Sartorius and BioIVT, this webinar will explore the opportunities and challenges that exist within cancer research drug discovery and development.

You will hear from Dr Sudha Rao, Chief Scientific Officer of Kazia Therapeutics, Karol Budzik, PhD, Business Development Associate at Vyriad Therapeutics and Lars van der Veen, Chief Scientific Officer at iOnctura.

Presentations will cover how cancer treatments have shifted towards reprogramming the biology driving tumour growth, immune escape and treatment resistance, the trajectory that in vivo CAR-T treatments are taking, and how challenging tumours burdened by stroma and immune-mediated resistance can be tackled.

Q&A with the speakers follows the presentations.

Register for free now.

The post New webinar: Tackling drug discovery challenges in cancer research appeared first on Drug Discovery World (DDW).

Continue Reading

Uncategorized

Psilocybin proves promising in neuropathic pain mouse study

Published

on

Amid the rise of psychedelics in the mental health space, researchers have begun to explore psilocybin as a treatment for chemotherapy-induced peripheral neuropathy.

Continue Reading

Uncategorized

New Spectrometry Technique Could Aid Formulation Development

New Spectrometry Technique Could Aid Formulation Development

Published

on

A new technique combining two forms of spectrometry could help biopharmaceutical companies improve their choice of formulation buffer for antibody manufacturing by revealing how molecular forms and three-dimensional shapes of complex biologics respond to their environment. That’s the view of Christian Bleiholder, PhD, a professor at Florida State University who helped develop the technique.

According to Bleiholder, what happens structurally when a complex biological molecule, such as an antibody or viral spike protein, binds to its target is currently poorly understood.

“This is where [this approach] can help with the bioprocessing and formulation,” he says, as structural changes “can affect the lifespan [of the product] and lead to issues, such as aggregation.”

Because antibodies are complex, existing techniques tend to be powerful at different levels of complexity, he explains. Mass spectrometry is particularly powerful for distinguishing molecular composition, while structural approaches such as X-ray crystallography and cryo-electron microscopy can provide high-resolution structural information.

The challenge is understanding the link between these things within a heterogeneous sample, he says.

To overcome this, Bleiholder and his team worked with Bruker Daltonics to develop Tandem-Trapped Ion Mobility Spectrometry (Tandem-TIMS). This combines tandem ion mobility spectrometry with tandem mass spectrometry to disentangle three overlapping layers of molecular complexity: molecular form, three-dimensional shape, and binding or assembly state, he says.

He explains that, if the proteins have different structures, they can be characterized with tandem ion mobility spectrometry, and then mass spectrometry can be used to look at their molecular forms and binding states.

Going forward, Bleiholder hopes the technique can be used for formulation development but also earlier, during drug discovery of new products, such as multi-specific antibodies, to determine which molecular states are important and how those change when a biologic engages its target. He also plans to look at automating the technique.

Bleiholder spoke about using Tandem-TIMS at the Bioprocessing Summit in Boston earlier this year.

The post New Spectrometry Technique Could Aid Formulation Development appeared first on GEN – Genetic Engineering and Biotechnology News.

Continue Reading

Trending

Helixgate Biotech Review July Issue QR CodeScan to Read